Mark Voll
CIK: 0001207512
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RenovoRx, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 10, 2026RNXT
RenovoRx, Inc.
Award(A)Direct80K shares- - May 19, 2026RNXT
RenovoRx, Inc.
Purchase(P)Direct25K shares at avg. $0.79$20K - Apr 3, 2026RNXT
RenovoRx, Inc.
Award(A)Direct80K shares- - Mar 25, 2026RNXT
RenovoRx, Inc.
Award(A)Direct12.4K shares- - Mar 20, 2026RNXT
RenovoRx, Inc.
Purchase(P)Indirect97.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 | RNXT RenovoRx, Inc. | Award(A) | 80,000 | - | $0 | Direct |
| May 19, 2026 | RNXT RenovoRx, Inc. | Purchase(P) | 25,000 | $0.79 | $19,690 | Direct |
| Apr 3, 2026 | RNXT RenovoRx, Inc. | Award(A) | 80,000 | - | $0 | Direct |
| Mar 25, 2026 | RNXT RenovoRx, Inc. | Award(A) | 12,380 | - | $0 | Direct |
| Mar 20, 2026 | RNXT RenovoRx, Inc. | Purchase(P) | 97,200 | - | $0 | Indirect |
1-5 of 5 transactions
About VOLL MARK
VOLL MARK (SEC CIK 0001207512) files insider reports with the SEC as Chief Financial Officer of RenovoRx, Inc. (RNXT).
Signal8 holds 7 ownership filings by VOLL MARK (2 Form 3, 5 Form 4), filed between Mar 24, 2026 and Sep 15, 2026. Those filings report 5 transactions, from Mar 20, 2026 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on VOLL MARK's filings is in MOUNTAIN VIEW, CA.
Recent filings by VOLL MARK
- Sep 10, 2026: Grant or award of RNXT shares (Form 4, code A).
- May 19, 2026: Open-market purchase of RNXT shares (Form 4, code P).
- Apr 3, 2026: Grant or award of RNXT shares (Form 4, code A).
- Mar 25, 2026: Grant or award of RNXT shares (Form 4, code A).
- Mar 20, 2026: Open-market purchase of RNXT shares (Form 4, code P).
Other insiders filing for RenovoRx, Inc. (RNXT)
- Macfarlane K. Angela, Director
- Spiegel Robert J., Director
- RYAN UNA S, Director
- Marton Laurence, Director
- Bagai Shaun, Chief Executive Officer
- Gentry Leesa, Chief Clinical Officer